Nat Commun April 2023 PMID 37080958

CAR-neutrophil mediated delivery of tumor-microenvironment responsive nanodrugs for glioblastoma chemo-immunotherapy.

Yun Chang, Xuechao Cai, Ramizah Syahirah, Yuxing Yao, Yang Xu, Gyuhyung Jin, Vijesh J Bhute, Sandra Torregrosa-Allen, Bennett D Elzey, You-Yeon Won, Qing Deng, Xiaojun Lance Lian, Xiaoguang Wang, Omolola Eniola-Adefeso, Xiaoping Bao

Download social card

Mentions

Peak: 3 in Apr 2023

across 3 sources since Apr 2023

Extended reach

1,243

potential audience

Total likes

Video views

Mentions per month

Apr 2023 – Jul 2023

Where it's discussed

X / Twitter3 posts
Blogs2 articles
YouTube1 videos

AI synopsis

What people are saying

Comments reflect strong support for the publication's groundbreaking approach, with phrases like 'game-changing' and 'promising breakthrough' demonstrating excitement and recognition of its potential impact. The interest and engagement are evident in detailed discussions about how CAR-neutrophils could overcome treatment barriers, showing that users find the research both fascinating and potentially transformative.

AgreementStrong agreement

Comments overwhelmingly support the significance of the research, emphasizing its innovative approach and promising results.

InterestHigh interest

Discussion threads show high curiosity and enthusiasm about the potential applications in glioblastoma treatment.

EngagementModerate engagement

Many posts delve into technical details, discussing the mechanisms of CAR-neutrophils and nanodrug delivery, indicating active engagement.

ImpactHigh impact

Posts highlight the potential for this research to revolutionize brain tumor therapy, suggesting a high impact on future treatment strategies.

Abstract in brief

Glioblastoma (GBM) is a highly aggressive brain tumor that poses treatment challenges due to barriers in the brain that limit the effectiveness of traditional therapies.
Researchers are using genetically engineered human pluripotent stem cells to create CAR-neutrophils, which can effectively target GBM by delivering nanodrugs directly to the tumor site without causing additional inflammation.
The approach shows promising results in reducing drug delivery to off-target areas and improving treatment outcomes in tumor-bearing mice, highlighting a potential new platform for GBM therapy and possibly other diseases.

Read the full abstract

All mentions

Neutrophil-Driven Delivery of Tumor-Responsive Nanodrugs for Glioblastoma Treatment

Researchers utilize CAR-neutrophils derived from engineered stem cells to deliver nanodrugs directly to glioblastoma tumors, overcoming brain barriers. This promising approach may enhance targeted chemoimmunotherapy for…

STEM RTCL TV · Jul 19, 2023 2 views

Brain tumor ULisboa

@braintumor_UL · X

CAR-neutrophil mediated delivery of tumor-microenvironment responsive nanodrugs for glioblastoma chemo-immunotherapy https://t.co/HOpEruQBtO

Apr 21, 2023 · 248 followers View post →

minnlab_litbot

@MLitbot · X

CAR-neutrophil mediated delivery of tumor-microenvironment responsive nanodrugs for glioblastoma chemo-immunotherapy https://t.co/Mihp2FKPJZ https://t.co/BSk9KCZ0nb

Apr 21, 2023 · 72 followers View post →

LUKMAN AFOLABI

@saintlukman · X

CAR-neutrophil mediated delivery of tumor-microenvironment responsive nanodrugs for glioblastoma chemo-immunotherapy https://t.co/obecOp0sez https://t.co/FeaUotAMi5

Apr 20, 2023 · 922 followers View post →